

ACT-A Updates

Member State COVID-19 Information Session

24 June 2021

ACT now, ACT together to accelerate the end of the COVID-19 crisis

ACT-A – Updates & Events

1. ACT-A Financing & Advocacy - recent events
2. COVAX – new supply forecast issued (23 June)
3. ACT-A Strategic Review – in planning (Jul-Sep)
4. Special ACT-A Council Briefing of WHO Member States (6 Jul)
5. Next week & beyond

5 major ACT-A events of past 3 weeks

Emphasis: equity for Vaccines, tests, treatments & PPE



G20/EC Global Health Summit
(21 May)



IMF "Proposal to end the Pandemic" (21 May & 1 Jun)



World Health Assembly incl. IPPPR (24 May – 1 Jun)



Gavi COVAX AMC Summit
(2 June)



G7 Summit
(11-13 June)

G7 Leaders' Summit Communique

Reaffirmed crucial role of ACT-A & announced dose-sharing

“We reaffirm our support for all pillars of the ACT-A across, treatments, tests and strengthening public health systems as well as vaccines.”

G7 main ACT-A/COVAX outcomes

- **870m¹** ‘donated doses’ (>500 m of which additional)
- primarily through **COVAX**
- **>1/2** of these doses in 2021

1. Includes contributions announced for Carbis Bay: US - 500m doses, of which 200m by end 2021; UK - 100m doses, of which 30m by end 2021., France - 30m by end 2021 (+30m already committed, total 60m) ; Canada - 13m doses ; Australia - >20 m doses; Republic of Korea - \$100m in 2021, equivalent to 18 m doses. Commitment to a further \$100m vaccines in 2022.


2. 2. For Gavi AMC : USD 100m in 2021 and USD 100m in 2022

COVAX: new supply forecast issued 23 June


<https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20Forecast.pdf>




By AMC/SFP/donations




By Product



By WHO Region



By contract status



There are still substantial risks to *projected* supply. Deep dive with Gavi next week. A new commitment of manufacturers & contracting & producing countries vital!

ACT-A Strategic Review: context

Given the ongoing pandemic and need for more equitable access to COVID-19 tools, **stakeholders have proposed a strategic review** of ACT-Accelerator to **inform decision-making** about its current operating model & **potential role beyond the 1st quarter of 2022**

ACT-A Strategic Review: status of planning

Objectives/dimensions:

1. results against the 2 major ACT-A objectives (acceleration & equity)
2. impact of ACT-A construct & operating model
3. impact of ACT-A financing (inc. pledges, funding rec. & exp).
4. impact of broader ecosystem
5. recommendations for current ACT-A & potential role beyond Q1 2022

Management arrangements:

- Sponsors: invite the 3 WHO Special Envoys for ACT-A (current & Emeritus)
- Reference group: co-hosts, co-convening agencies, council, industry, CSO & Hub reps
- Implementation: external firm with no role in ACT-A

Timeline: (i) targeted RFP in June (ii) contract firm & initiate in Jul (iii) report in Sept

Next steps: share concept note & engage further during inception phase

Special ACT-A Facilitation Council Briefing of WHO Member States

6 July 2021, 12.30 -15.00 (CEST)

Agenda

- current **vaccines coverage, COVAX vaccine supply** outlook & urgent needs
- most urgent needs & **funding requirements for COVID-19 tests, treatments & PPE**
- updates on:
 - ACT-A Strategic Review
 - ACT-A Quarterly Impact Report
 - Health Systems Connector workplan
 - Plans for the 7th Council

ACT-A & MS COVID-19 Briefings

Next week:

Interim & Phase 2 allocation criteria for COVAX

COVAX Supply Forecast & risk mitigation (with Gavi)

mRNA Tech Transfer Hub

Upcoming:

Health Systems Connector nearterm workplan (Jul-Dec 2021)
